KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) major shareholder Holdings A/S Novo sold 25,900 shares of the firm’s stock in a transaction on Wednesday, September 13th. The shares were sold at an average price of $8.02, for a total value of $207,718.00. Following the transaction, the insider now directly owns 2,876,027 shares of the company’s stock, valued at approximately $23,065,736.54. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Holdings A/S Novo also recently made the following trade(s):

  • On Thursday, September 14th, Holdings A/S Novo sold 10,000 shares of KalVista Pharmaceuticals stock. The shares were sold at an average price of $8.05, for a total value of $80,500.00.
  • On Friday, September 15th, Holdings A/S Novo sold 176,647 shares of KalVista Pharmaceuticals stock. The shares were sold at an average price of $7.21, for a total value of $1,273,624.87.

Shares of KalVista Pharmaceuticals, Inc. (KALV) traded down 13.11% during trading on Friday, hitting $6.96. The stock had a trading volume of 162,624 shares. The stock has a 50-day moving average price of $8.20 and a 200 day moving average price of $7.83. KalVista Pharmaceuticals, Inc. has a 12 month low of $6.09 and a 12 month high of $10.65. The company’s market cap is $67.60 million.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its earnings results on Thursday, September 14th. The specialty pharmaceutical company reported ($0.51) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.59) by $0.08. KalVista Pharmaceuticals had a negative return on equity of 57.41% and a negative net margin of 4,191.47%. The business had revenue of $0.10 million during the quarter. Equities analysts expect that KalVista Pharmaceuticals, Inc. will post ($2.94) EPS for the current fiscal year.

WARNING: “KalVista Pharmaceuticals, Inc. (KALV) Major Shareholder Holdings A/S Novo Sells 25,900 Shares of Stock” was posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/09/16/kalvista-pharmaceuticals-inc-kalv-major-shareholder-holdings-as-novo-sells-25900-shares-of-stock.html.

A hedge fund recently bought a new stake in KalVista Pharmaceuticals stock. Eventide Asset Management LLC bought a new position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) in the 1st quarter, according to its most recent filing with the SEC. The institutional investor bought 98,100 shares of the specialty pharmaceutical company’s stock, valued at approximately $766,000. Eventide Asset Management LLC owned 1.01% of KalVista Pharmaceuticals at the end of the most recent quarter. Institutional investors own 75.66% of the company’s stock.

Several brokerages have commented on KALV. ValuEngine raised KalVista Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, August 2nd. BTIG Research started coverage on KalVista Pharmaceuticals in a report on Thursday, August 31st. They set a “buy” rating and a $18.00 price target for the company.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, formerly Carbylan Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME).

Receive News & Ratings for KalVista Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.